Last reviewed · How we verify
INV-202
At a glance
| Generic name | INV-202 |
|---|---|
| Also known as | None applicable |
| Sponsor | Inversago Pharma Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease (PHASE2)
- Study of INV-202 in Patients With Obesity and Metabolic Syndrome (PHASE2)
- A Study to Explore the PK and PD of INV-202 in Metabolic Syndrome (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- INV-202 CI brief — competitive landscape report
- INV-202 updates RSS · CI watch RSS
- Inversago Pharma Inc. portfolio CI